Dosing & Uses
Myelofibrosis
Pending FDA approval for myelofibrosis in patients with severe thrombocytopenia (platelet counts <50,000/mm3)
Next:
Pharmacology
Mechanism of Action
Tyrosine kinase inhibitor (TKI); inhibits 4 mutations of the JAK signal transduction pathways (ie, JAK2, FLT3, IRAK1 and CSF1R); mutations in these kinases have been shown to be related to a the development of a variety of blood-related cancers, including myelofibrosis
The JAK family of enzymes is critical for normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses
Previous
Next:
Images
Previous
Next:
Patient Handout
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
